Research Topics
| Russell PortenoySummaryAffiliation: Beth Israel Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Advances in cancer pain managementAnnette Vielhaber
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, First Avenue at 16th Street, New York, NY 10003, USA
Hematol Oncol Clin North Am 16:527-41. 2002..With a detailed assessment, clinicians should be able to choose among the large and diverse group of options available and implement an approach, or combination of approaches, that have a high probability of improving analgesic outcomes...
Appropriate use of opioids for persistent non-cancer painRussell K Portenoy
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY 10003, USA
Lancet 364:739-40. 2004
A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer painRussell K Portenoy
Beth Israel Medical Center, New York, NY 10003, USA
Pain 151:617-24. 2010..In this short-term study, FPNS was safe, well tolerated, and rapidly efficacious for BTCP...
Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry studyRussell K Portenoy
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY 10003, USA
Clin J Pain 23:287-99. 2007..To evaluate the outcomes associated with the use of controlled-release (CR) oxycodone for up to 3 years in the treatment of noncancer pain...
Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer painRussell K Portenoy
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY 10003, USA
J Pain 7:583-91. 2006..These findings will assist clinicians in assessing and managing this type of pain...
Opioid use and survival at the end of life: a survey of a hospice populationRussell K Portenoy
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York 10003, USA
J Pain Symptom Manage 32:532-40. 2006..In a hospice population, survival is influenced by complex factors, many of which may not be measurable. Based on these findings, concern about hastening death does not justify withholding opioid therapy...
A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancerRussell K Portenoy
Beth Israel Medical Center, New York, NY 10003, USA
Clin J Pain 22:805-11. 2006..This double-blind, randomized, placebo-controlled study evaluated the efficacy, safety, and tolerability of FBT in opioid-treated patients with cancer-related BTP...
Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled studyRussell K Portenoy
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY 0003, USA
Curr Med Res Opin 23:223-33. 2007..FBT was evaluated for BTP in opioid-treated patients with chronic low back pain--the first such study in a population with chronic non-cancer pain...
Development and testing of a neuropathic pain screening questionnaire: ID PainRussell Portenoy
Beth Israel Medical Center, First Avenue at 16th Street, New York, NY 10003, USA
Curr Med Res Opin 22:1555-65. 2006..A second multicenter study evaluated reliability and validity. Patients (N = 308) treated by pain specialists completed ID Pain and validation measures...
Safety and tolerability of high doses of intrathecal fentanyl for the treatment of chronic painSulane Do Ouro
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY, USA
J Opioid Manag 2:365-8. 2006..Our experience highlights an expanding scope of practice in the use of IT opioids in general and fentanyl specifically and suggests that high-dose fentanyl can be used safely in highly selected patients...
Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositisLauren Shaiova
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, First Avenue at 16th Street, New York, NY 10003, USA
Support Care Cancer 12:268-73. 2004..OTFC is effective for breakthrough pain and could be particularly useful in patients with mucositis...
Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilitiesAndrew Rosenblum
Institute for Treatment and Services Research, National Development and Research Institutes, New York, NY 10010, USA
JAMA 289:2370-8. 2003..Little is known about the prevalence and characteristics of chronic pain among patients with different types of chemical dependency...
Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: impact on function, mood, and quality of lifeRussell K Portenoy
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York, USA
J Opioid Manag 6:109-16. 2010..Very few studies have evaluated BTP in populations with chronic noncancer pain. Data that illuminate the impact of BTP may not generalize to other, less selected patient populations...
Pain in underserved community-dwelling Chinese American cancer patients: demographic and medical correlatesLara Dhingra
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, 120 East 16th Street, 12th Floor, New York, New York 10003, USA
Oncologist 16:523-33. 2011..The objective of this study was to describe the epidemiology of pain in this population. This information is needed to identify and address unmet clinical needs for culturally relevant interventions targeting pain and its consequences...
Administration of morphine sulfate extended-release capsules via gastrostomy: dissolution study and case reportsLauren Shaiova
Department of Pain Medicine and Palliative Care, Metropolitan Hospital Center, New York, New York 10019, USA
J Palliat Med 10:1063-7. 2007..However, a larger study sample will need to be investigated to determine efficacy in this type of delivery system for cancer pain relief in this population of patients undergoing radiation treatment for head and neck cancers...
Adjuvant analgesics in cancer pain managementDavid Lussier
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, First Avenue at 16th Street, New York, New York 10003, USA
Oncologist 9:571-91. 2004..This article reviews the evidence supporting the use of each class of adjuvant analgesic for the treatment of pain in cancer patients and provides a comprehensive outline of dosing recommendations, side effects, and drug interactions...
A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosisBrenda Breuer
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York 1003, USA
Clin Ther 29:2022-30. 2007..Approximately 30% of patients with multiple sclerosis (MS) have central pain (CP). The anticonvulsant lamotrigine has been shown to be efficacious in some types of CP, but its efficacy in MS-related CP has not been confirmed...
Monitoring outcomes during long-term opioid therapy for noncancer pain: results with the Pain Assessment and Documentation ToolSteven D Passik
Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Opioid Manag 1:257-66. 2005..e., addiction or diversion) in only approximately 10 percent of cases. Using the PADT physician ratings can be developed in four domains. In this sample, outcomes suggested that opioid therapy provided meaningful analgesia...
Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging studyRussell K Portenoy
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York 10003, USA
J Pain Symptom Manage 35:458-68. 2008..In conclusion, methylnaltrexone relieved opioid-induced constipation at doses >or=5mg in patients with advanced illness, and did not reduce analgesia or cause opioid withdrawal symptoms...
L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled studyRicardo A Cruciani
Research Division, Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY 10003, USA
J Pain Symptom Manage 37:622-31. 2009....
Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristicsRussell K Portenoy
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York, USA
J Opioid Manag 6:97-108. 2010..Studies in noncancer populations are limited to surveys of pain clinics and patients with other advanced diseases. To better understand BTP, data are needed from less selected populations...
Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II studyRicardo A Cruciani
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York 10003, USA
J Pain Symptom Manage 32:551-9. 2006..This study provides the basis for the design of future placebo-controlled studies of l-carnitine supplementation for cancer-related fatigue...
U.S. board-certified pain physician practices: uniformity and census data of their locationsBrenda Breuer
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY 10003, USA
J Pain 8:244-50. 2007..The location of pain management practices largely corresponds to census data, with the exception of underrepresentation in rural areas...
Pain management by primary care physicians, pain physicians, chiropractors, and acupuncturists: a national surveyBrenda Breuer
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY 10003, USA
South Med J 103:738-47. 2010....
Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe painRussell K Portenoy
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY 10003, USA
J Pain Symptom Manage 23:292-300. 2002..The pharmacodynamic implications of this profile deserve further study...
Developing an integrated Department of Pain and Palliative MedicineRussell Portenoy
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York 10003, USA
J Palliat Med 5:623-33. 2002
Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuseSteven D Passik
Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Clin J Pain 22:173-81. 2006..Treatment of substance abusers with pain requires skills that complement best practices in opioid prescribing. Better approaches to the long-term treatment of these populations are needed...
MMTP patients with chronic pain switching to pain management clinics. A problem or an acceptable practice?Ricardo A Cruciani
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York 10003, USA
Pain Med 9:359-64. 2008..Research is needed to evaluate the phenomenology of pain and addiction in this population and the outcomes associated with varied therapeutic strategies...
Opioids and the treatment of chronic pain: controversies, current status, and future directionsAndrew Rosenblum
National Development and Research Institutes, New York, NY 10010, USA
Exp Clin Psychopharmacol 16:405-16. 2008....
Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patientsRussell K Portenoy
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York, USA
J Opioid Manag 6:319-28. 2010..to assess the long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray (FPNS) in patients with breakthrough cancer pain (BTCP)...
Improving end-of-life care: development and pilot-test of a clinical pathwayMarilyn Bookbinder
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York 10003, USA
J Pain Symptom Manage 29:529-43. 2005..Further study of this systems-oriented approach to change is warranted and should include direct assessment of patient and family outcomes, as well as measures of process...
Opioid rotation in the management of refractory cancer painRose Anne Indelicato
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY 10003, USA
J Clin Oncol 21:87s-91s. 2003
Cancer pain managementRussell K Portenoy
Beth Israel Medical Center, New York, NY 10003, USA
Clin Adv Hematol Oncol 3:30-2. 2005
Population-based survey of pain in the United States: differences among white, African American, and Hispanic subjectsRussell K Portenoy
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY 10003, USA
J Pain 5:317-28. 2004..Race and ethnicity were not independently associated with severe pain, but both minorities were more likely to possess the socioeconomic and educational characteristics that were associated...
Access to care for chronic pain: racial and ethnic differencesMarisa Nguyen
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York 10003, USA
J Pain 6:301-14. 2005..A national telephone survey suggests that race and ethnicity, along with other demographic and socioeconomic factors, influence access to care for chronic pain...
Prevalence and characteristics of chronic pain in patients admitted to an outpatient drug and alcohol treatment programRobert Sheu
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York 10003, USA
Pain Med 9:911-7. 2008..To evaluate the prevalence, characteristics, and correlates of chronic pain in a population of predominantly employed, alcoholic patients attending an outpatient drug and alcohol treatment program...
Opioid rotation: the science and the limitations of the equianalgesic dose tableHelena Knotkova
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY, USA
J Pain Symptom Manage 38:426-39. 2009..Review of these issues informs the use of opioid rotation in the clinical setting and defines key areas for future research...
Measurement of QTc in patients receiving chronic methadone therapyRicardo A Cruciani
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York 10003, USA
J Pain Symptom Manage 29:385-91. 2005..Significant dose response was observed in males on methadone <12 months (rho=0.60, P=0.02). Our study suggests that methadone may prolong the QTc interval in specific subpopulations but poses little risk of serious prolongation...
Opioid rotation in the management of refractory cancer painRose Anne Indelicato
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, First Ave. at 16th Street, New York, NY 10003, USA
J Clin Oncol 20:348-52. 2002
Management of fatigue in the cancer patientPauline Lesage
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York 10003, USA
Oncology (Williston Park) 16:373-8, 381; discussion 381-2, 385-6, 388-9. 2002..Symptomatic interventions include specific drug treatment, modification of activity, exercise, and cognitive therapies...
Development of a brief assessment scale for caregivers of the medically illMyra Glajchen
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York 10003, USA
J Pain Symptom Manage 29:245-54. 2005..005; female caregivers, P=0.035). These results support the validity of the BASC as a brief instrument for caregiver burden...
How to use antidepressants and anticonvulsants as adjuvant analgesics in the treatment of neuropathic cancer painAmy A McDonald
VA Western New York Healthcare System, USA
J Support Oncol 4:43-52. 2006
Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trialJoseph S Gimbel
Arizona Research Center, LLC, Phoenix, USA
Neurology 60:927-34. 2003..CONCLUSIONS: In this 6-week trial, CR oxycodone was effective for the treatment of moderate to severe pain due to diabetic neuropathy. Adverse events were typical of opioid-related side effects...
Toward optimal health: the experts discuss chronic pain. Interview by Jodi Godfrey MeislerRussell K Portenoy
J Womens Health Gend Based Med 11:341-5. 2002
Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant painMark Palangio
Abbott Laboratories, Morris Corporate Center, Parsippany, New Jersey 07054, USA
J Pain Symptom Manage 23:355-68. 2002..Controlled longitudinal studies are required to further evaluate the use of ER hydromorphone in patients with discrete chronic malignant or nonmalignant pain conditions...
The measurement of symptoms in young children with cancer: the validation of the Memorial Symptom Assessment Scale in children aged 7-12John J Collins
Pain and Palliative Care Service, The Children's Hospital at Westmead, Sydney, New South Wales 2145, Australia
J Pain Symptom Manage 23:10-6. 2002..Systematic symptom assessment may be useful in future epidemiological studies of symptoms and in cancer chemotherapy drug trials...
A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapySteven D Passik
Symptom Management and Palliative Care Program, Markey Cancer Center, University of Kentucky, 800 Rose Street, CC449, Lexington, KY 40536 0093, USA
Clin Ther 26:552-61. 2004..During long-term treatment, this assessment should focus on a broad range of outcomes, each of which should be documented in the medical record...
Breakthrough pain characteristics and syndromes in patients with cancer pain. An international surveyAugusto Caraceni
Neurology Unit Pain Therapy and Palliative Care Unit, National Cancer Institute of Milan, Via Venezian 1, Milan, Italy
Palliat Med 18:177-83. 2004..Further studies are needed to characterize subtypes of BKP. The uneven distribution of BKP reporting across pain specialists from different countries suggests that more standardized methods for diagnosing BKP are needed...
Strengthening communitiesRussell K Portenoy
J Palliat Med 11:671-2. 2008
Formal ABMS and ACGME recognition of hospice and palliative medicine expected in 2006Russell K Portenoy
J Palliat Med 9:21-3. 2006
Pharmacologic management of neuropathic pain: evidence-based recommendationsRobert H Dworkin
University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Pain 132:237-51. 2007..Long-term studies, head-to-head comparisons between medications, studies involving combinations of medications, and RCTs examining treatment of central NP are lacking and should be a priority for future research...
The road to formal recognition: the end is in sightRussell K Portenoy
American Board of Hospice and Palliative Medicine
J Palliat Med 8:266-8. 2005
Pain medicine and drug law enforcement: an important step toward balanceDavid E Joranson
J Pain Palliat Care Pharmacother 19:3-5. 2005
Myths about controlling painJune H Dahl
University of Wisconsin-Madison, USA
J Pain Palliat Care Pharmacother 18:55-8. 2004..Myths and misinformation about pain and its management often lead to poor therapy for patients in pain. Nine common myths about pain and its management are described and refuted...
Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery-- report of an expert panelSamuel J Hassenbusch
Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, 77030, USA
J Pain Symptom Manage 27:540-63. 2004..Based on the best available evidence and expert opinion, consensus recommendations were developed in all these areas. The panel's conclusions may provide a foundation for clinical practice and a rational basis for new research...
Creating a shared visionRussell K Portenoy
J Palliat Med 11:410-2. 2008
Drug-induced prolongation of the QT intervalRicardo A Cruciani
N Engl J Med 350:2618-21; author reply 2618-21. 2004
Symptom distress and quality of life in patients with advanced congestive heart failureCraig D Blinderman
Palliative Care Service, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
J Pain Symptom Manage 35:594-603. 2008..A focus on ameliorating prevalent physical symptoms and psychological distress, along with supportive measures that promote functional mobility, may lead to an improvement in the overall quality of life in this patient population...
